SCHEMBL318862

SCHEMBL318862

COC(=O)[C@H](N)c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.64
TSHR P16473 3/20 0.49
CYP1A2 P05177 2/20 0.49
CYP2D6 P10635 2/20 0.49
CYP3A4 P08684 1/20 0.49
MAPK1 P28482 1/20 0.49
HSD17B10 Q99714 1/20 0.49
MEN1 O00255 2/20 0.47
ALDH1A1 P00352 2/20 0.47
PTGS1 P23219 1/20 0.47
PTGS2 P35354 1/20 0.47
LMNA P02545 1/20 0.47
PKM P14618 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
CTSD P07339 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL283419 1.00 KMT2A (0.64) KMT2ATSHRCYP1A2CYP2D6CYP3A4
SCHEMBL318460 1.00 KMT2A (0.64) KMT2ATSHRCYP1A2CYP2D6CYP3A4
SCHEMBL29841724 1.00 KMT2A (0.64) KMT2ATSHRCYP1A2CYP2D6CYP3A4
Hydrochloric Acid SCHEMBL852494 0.98 KMT2A (0.62) KMT2ATSHRCYP1A2CYP2D6CYP3A4
Hydrochloric Acid SCHEMBL1143309 0.98 KMT2A (0.62) KMT2ATSHRCYP1A2CYP2D6CYP3A4
Hydrochloric Acid SCHEMBL852495 0.98 KMT2A (0.62) KMT2ATSHRCYP1A2CYP2D6CYP3A4
SCHEMBL7252180 0.89 KMT2A (0.48) KMT2ATSHRCYP1A2CYP2D6CYP3A4
SCHEMBL5514179 0.89 KMT2A (0.52) KMT2ACYP1A2CYP3A4ALDH1A1PTGS2
Cadaverine Tartrate SCHEMBL32662849 0.88 KMT2A (0.51) KMT2ATSHRCYP1A2CYP2D6CYP3A4
SCHEMBL27865114 0.86 KMT2A (0.53) KMT2ATSHRCYP1A2CYP2D6CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12636386-B2 Compositions and methods for the treatment and imaging of cancer BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 2026-05-26 US disclosed
US-20260117216-A1 MUTANT PENICILLIN ACYLASE AND USES THEREOF XINGZHI COLLEGE ZHEJIANG NORMAL UNIVERSITY (CN) 2026-04-30 US disclosed
US-12059422-B2 (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases MEI PHARMA, INC. (US) 2024-08-13 US disclosed
US-20240208959-A1 THIAZOLE/ISOTHIAZOLE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2024-06-27 US disclosed
US-20240208959-A1 THIAZOLE/ISOTHIAZOLE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2024-06-27 US disclosed
US-20240208959-A1 THIAZOLE/ISOTHIAZOLE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2024-06-27 US disclosed
EP-4319872-A1 THIAZOLE/ISOTHIAZOLE HSD17B13 INHIBITORS AND USES THEREOF Inipharm, Inc. (US) 2024-02-14 EP disclosed
US-20230242482-A9 DISCOVERY, TOTAL SYNTHESIS, AND BIOACTIVITY OF DOSCADENAMIDES UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2023-08-03 US disclosed
US-20230159538-A1 PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS GLOBAL BLOOD THERAPEUTICS, INC. 2023-05-25 US disclosed
US-20230159538-A1 PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS GLOBAL BLOOD THERAPEUTICS, INC. 2023-05-25 US disclosed
EP-0983999-A1 PROCESS FOR PRODUCING AMIDE DERIVATIVES AND INTERMEDIATES Japan Tobacco Inc. (JP) 2000-03-08 EP disclosed
EP-0984000-A1 PROCESS FOR PRODUCING AMIDE DERIVATIVES AND INTERMEDIATE COMPOUNDS Japan Tobacco Inc. (JP) 2000-03-08 EP disclosed
US-6018066-A Production of amide derivatives and intermediate compounds therefor JAPAN TOBACCO INC. (JP) 2000-01-25 US disclosed
US-5962704-A Production of amide derivatives and intermediate compounds therefor JAPAN TOBACCO INC. (JP) 1999-10-05 US disclosed
US-5777129-A Hyperbranched polymers HOECHST CELANESE CORP. (US) 1998-07-07 US disclosed
EP-0846000-A1 HYPERBRANCHED POLYMERS HOECHST CELANESE CORPORATION (US) 1998-06-10 EP disclosed
US-5710282-A Process for preparing substituted aryls HOECHST CELANESE CORPORATION (US) 1998-01-20 US disclosed
WO-1997006825-A1 HYPERBRANCHED POLYMERS HOECHST CELANESE CORPORATION (US) 1997-02-27 WO disclosed
US-5591809-A Process for preparing hyperbranched polymers HOECHST CELANESE CORPORATION (US) 1997-01-07 US disclosed
US-5567795-A Process for preparing hyperbranched polymers HOECHST CELANESE CORPORATION (US) 1996-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12059422-B2 (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases CCNI, CCNK, CCNA1 KMT2A 2083/4885TSHR 3251/4885CYP1A2 224/4885
US-20260117216-A1 MUTANT PENICILLIN ACYLASE AND USES THEREOF ALPL, PEPD, ACSL6 KMT2A 142/4885TSHR 4555/4885CYP1A2 900/4885
US-20240208959-A1 THIAZOLE/ISOTHIAZOLE HSD17B13 INHIBITORS AND USES THEREOF HSD17B1, HSD17B3, HSD17B13 KMT2A 4050/4885TSHR 1734/4885CYP1A2 58/4885
US-20230242482-A9 DISCOVERY, TOTAL SYNTHESIS, AND BIOACTIVITY OF DOSCADENAMIDES PDE9A, CGAS, PDE8A KMT2A 3296/4885TSHR 1389/4885CYP1A2 2255/4885
US-20230159538-A1 PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS PDK1, PDK2, PKM KMT2A 1420/4885TSHR 2499/4885CYP1A2 3301/4885
US-12636386-B2 Compositions and methods for the treatment and imaging of cancer GBA1, GALC, CD47 KMT2A 872/4885TSHR 887/4885CYP1A2 2417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.